SLSN - Rasio utang marang kapitalisasi buku solesence.com

Logo grafis Solesence (SLSN)

The visualization of the market value of Solesence Inc (SLSN) on the GURU.Markets platform, which stands at 1.86, is based on the expansion of Solesence Inc (SLSN) within the innovative mineral skin filter segment. Growth is driven by the implementation of specialized component transportation that eliminates light exposure and oxidation. However, a narrow business profile and strict photoprotection requirements create certain challenges for the company's profit stability.

SLSN (Solesence) riwayat Utang marang nilai buku saka 09.04.2025 nganti 28.10.2026

solesence.com (SLSN) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:
Rega saham Solesence|SLSN - Prakiraan konsensus analis
- data kapitalisasi pasar:
Nilai pasar SLSN|SLSN - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Solesence Inc|SLSN - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku solesence.com|SLSN - Total Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Solesence Inc|SLSN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Solesence|SLSN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku SLSN
Ringkesan analitik perusahaan:Solesence Inc. SLSN
Barang utama Solesence

A stable staff of chemical engineers and FDA standards experts provides Solesence Inc. (SLSN) with a sustainable operational foundation devoid of critical competency shortages. The total liabilities-to-equity ratio, reflecting the degree of financial leverage and default risk, allows users via GURU.Markets tools to track changes in the proportion of total debt to book capitalization to assess the issuer's debt load.

Pesaing Solesence Inc

Utang-utang marang kapitalisasi buku KRYS (Krystal Biotech, Inc.)|apogeetherapeutics.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Arcutis Biotherapeutics, Inc. (ARQT)|VCEL: Rasio utang marang aset resik|ORKA (Oruka Corp) - Rasio utang marang kapitalisasi buku|Sanara MedTech (SMTI) - Utang marang nilai buku|DBVT (DBV Tech) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Journey Medical Corp. (DERM)|Forte Biosciences (FBRX) - Utang marang nilai buku|Rasio utang marang aset resik EMPG (Empro Group Inc.)|Rasio utang marang kapitalisasi buku SLGL|AXIL Brands Inc - Utang-utang marang aset resik|Medicus Pharma Ltd. - Rasio utang marang kapitalisasi buku|VRCA - Utang-utang marang kapitalisasi buku|hoththerapeutics.com - Utang-utang marang kapitalisasi buku|BFRI (Biofrontera) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku VYNE Therapeutics, Inc. (VYNE)|Rasio utang marang nilai buku SNOA|QNRX (Quoin Pharmaceuticals) - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik AZTR (azitrainc.com)|DRMA: Rasio utang marang kapitalisasi buku|Elevai Labs Inc - Utang-utang marang nilai buku|RVNC - Rasio utang marang kapitalisasi buku